CRVS Short Positions, Funds Shorting Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US2210151005

Fonds shorting Corvus Pharmaceuticals, Inc.

Denne siden viser institusjoner, fonds og hovedaksjonærer som har rapportert short-posisjoner i deres siste rapporteringsperiode. Vi betrakter .......... som short- posisjoner og inkluderer alle institusjoner som har offentliggjort putopsjoner her. Grønne rader indikerer nye posisjoner. Røde rader indikerer lukkede posisjoner. Klikk på linkikonet for å se full transaksjonshistorikk.

Oppgraderfor å låse opp premiedata.

Fildato Kilde Investor Type Gjennomsnittlig pris
(estimert)
Aksjer Δ Aksjer
(%)
Rapportert verdi ($1000) Verdi (%) Portallokering (%)
2025-08-14 13F Group One Trading, L.p. Put 14 700 −77,99 59 −72,64
2025-08-14 13F Jane Street Group, Llc Put 0 −100,00 0
2025-08-12 13F Proequities, Inc. Put 0 0
2025-08-14 13F Citadel Advisors Llc Put 38 200 −63,51 153 −54,22
2025-05-15 13F ADAR1 Capital Management, LLC Put 0 −100,00 0 −100,00
2025-05-15 13F LMR Partners LLP Put 0 −100,00 0 −100,00
2025-08-14 13F B Group, Inc. Put 0 −100,00 0 −100,00
2025-08-18 13F Wolverine Trading, Llc Put 10 500 −21,05 41 −9,09
2025-08-14 13F Ikarian Capital, LLC Put 0 −100,00 0
2025-08-14 13F Millennium Management Llc Put 150 000 200,00 600 277,36
2025-08-05 13F Simplex Trading, Llc Put 12 000 −89,27 0
2025-08-14 13F Boothbay Fund Management, Llc Put 0 −100,00 0
2025-08-14 13F Susquehanna International Group, Llp Put 27 400 −70,60 110 −63,18
Other Listings
DE:C17 € 5,14
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista